JaniceLGabriloveMD

Hematologic Oncology

Professor of Medicine, Mount Sinai School of Medicine

Overview of Dr. Gabrilove

Janice L. Gabrilove, M.D., is a world-renowned expert on the role of hematopoietic growth factors in normal and malignant hematopoiesis; and the role of these cytokines in ameliorating disease and treatment-related myelosuppression. She previously served on the faculty at Memorial Sloan-Kettering Cancer Center, where she rose to the rank of Associate Professor of Medicine. In 1998, she was recruited to The Mount Sinai School of Medicine as The James F. Holland Professor of Medicine, and Chief of the Division of Medical Oncology. She presently serves as the Associate Director, Education & Training for the Tisch Cancer Institute, an NCI-Designated Cancer Center at the Icahn School of Medicine at Mount Sinai. She also serves as the Director of the Clinical Research Education Program out of the Graduate School of Biomedical Sciences and oversees the Certificate, Masters of Science (MSCR) and PhD in Clinical Research.

Dr. Gabrilove is the recipient of a composition of matter and use patent for the discovery of human granulocyte colony stimulating factor (G-CSF), and was the first to demonstrate that it could alleviate certain harmful effects of chemotherapy on blood-cell production. G-CSF, now produced commercially by Amgen, Inc. under the trade-name Neupogen & Neulasta, is used worldwide as a supplement to chemotherapy. Dr. Gabrilove was the first to report on the ability of G-CSF to mobilize progenitors into the peripheral blood, an observation which has revolutionized the way in which bone-marrow transplantation is performed with the development of peripheral blood stem-cell transplants. Dr. Gabrilove has been awarded two additional patents for novel therapeutics fostering leukemic cell maturation, currently approved by the FDA, for the treatment of acute promyelocytic leukemia (APL).

Dr. Gabrilove is the recipient of numerous awards and presently holds 4 patents related to her work. She is a member of the American Society of Clinical Investigation

Office
1190 5th Avenue Guggenheim Pavill
Mount Sinai Hospitalruttenberg Treatment Center
New York, NY 10029
Book by Phone+1(650) 879-8502

Fax+1 212-423-0522

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1980 - 1984
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1977 - 1980
Icahn School of Medicine at Mount SinaiClass of 1977
Goucher CollegeB.A., 1969 - 1973

Certifications & Licensure

FL State Medical License 2020 - Present
NY State Medical License 1979 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Fellow American College of Physicians, 2013
Top Doctors: New York Metro Area Castle Connolly
America's Top Doctors for Cancer Castle Connolly, 2005-2017
America's Top Doctors Castle Connolly, 2002-2017
New York Magazine: Top Doctors Castle Connolly, 2002-2011, 2014
Department of Medicine Award for Outstanding Teaching MSSM, 2012
Dean’s Award for Senior Faculty Excellence in Teaching 2011
Clinician of the Year Award 2010
The Solomon Berson Award, Teaching Excellence 2005
International Health Professional of the Year 2004
Honorable mention, 2004 Excellence in Education Award The IME, The Mount Sinai School of Medicine, 2003
“Best Doctors in America” 2003
“Best Doctors” New York City Edition of Better Living Magazine, 2003
Excellence in Achievement Award 13th International Symposium on Treatment of Leukemia and Cancer, 2000
How To Find The Best Doctors, New York Metropolitan Area The Castle Connolly Guide, 1999
“Best Doctors” New York Magazine, 1999
The J. Lester Gabrilove Prize The Mount Sinai Hospital, 1997
Special Government Employee Center for Biologics Evaluation and Treatment, 1994
Elected Member The American Society for Clinical Investigation, 1993
The Jacobi Medallion The Mount Sinai Hospital, 1992
The Horowitz Prize Mt. Sinai School of Medicine, 1989
The Boyer Award for Clinical Investigation Memorial Sloan-Kettering Cancer Center, 1989
NCI Clinical Investigator, Physician Development Award (KO8) 1984
Junior Faculty Fellowship Award American Cancer Society, 1983
Rudin Fellowship 1983
The Harold Elster Memorial Award for the Highest Academic Standing in the Graduating Class Mount Sinai School of Medicine, 1977
The Janet M. Glasgow Award for “An Outstanding Woman in the Medical School Class” The American Medical Women's Association, 1977
Alpha Omega Alpha 1976
Phi Lambda Upsilon The National Honor Society of Chemistry, 1972
Join now to see all

Publications & Presentations

PubMed

91 citations
Cancer Incidence in World Trade Center Rescue and Recovery Workers, 2001–2008
Samara Solan, Sylvan Wallenstein, Moshe Shapiro, Susan L. Teitelbaum, Lori Stevenson
Environmental Health Perspectives. 2013-04-23
2515 citations
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker, François Guilhot, Stephen G. O'Brien, Insa Gathmann, Hagop M. Kantarjian
The New England Journal of Medicine. 2006-12-07
276 citations
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute mye...
Ellin Berman, G. Heller, J Santorsa, S McKenzie, Timothy Gee
Blood. 1991-04-15

Journal Articles

The Mentored-to-Independent Transition: Survey of Clinical and Translational Education and Career Development Leaders
Sweeney CS, Schwartz LS, Toto R, Fair A, Ahluwalia JS., Gabrilove JL, Acad Med, 1/1/2016
Sustaining the Clinical Translational Research Workforce: Training and Empowering
Yin HL, Gabrilove J, Jackson, Rebecca, Sweeney, C, Fair A, Toto R, Acad Med, 1/1/2015
Understanding Career Success and Contributing Factors for Clinical and Translational Investigators
Georgeanna FWB Robinson, EdD, Lisa S Schwartz, EdD, MS, Linda A DiMeglio, MD, MPH, Jasjit S Ahluwalia, MD, MPH, Janice L Gabrilove, MD, Academic Medicine, 1/1/2015
Research Mentor Training Curriculum
Pfund C, House S, Spencer K, Asquith P, Carney P, Masters KS, McGee R, Shanedling J, Vecchiarelli S, Fleming MA and the Mentoring Trial investigators, Clin Transl Sci, 1/1/2013
Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide treated myeloid leukemia and lymphoma cells: the role of glutathione s-transferase p1-1
Wang R, Liu C, Xia L, Zhao G, Gabrilove J, Waxman S, Jing Y, Clin Cancer Res, 1/1/2012
Phase II Trial of Histone Deacetylase Inhibitor Romidepsin for the Treatment of Refractory Multiple Myeloma
Ruben Niesvizky, Scott Ely, Tomer Mark, Sangeet Aggarwal, Janice L. Gabrilove, John J. Wright, Selina Chen-Kiang, Joseph A. Sparano, Cancer, 1/1/2011
Safety and Efficiancy of Romiplostim in Patients with Low-or Intermediate Risk Myelodysplastic Syndrome Receiving Azacitidine Therapy
Hagop M. Kantarjian, Frank Giles, Peter L. Greenberg, Ron L. Paquette, Eunice S. Wang, Janice L. Gabrilove, Guillermo Garica-Manero, Kuolung Hu, Janet L. Franklin, Die..., Blood, 1/1/2010
A Phase 2 single arm trial to evaluate the effectiveness of 13-week of darbepoetin alfa for correcting anemia in patients with myelodsplastic syndrome
Gabrilove, JL, Paquette R, Lyons R, Mushtaq C, Sekeres M, Lam H, Dreiling L, Br. J. Hematol, 1/1/2008
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-...
Moskowitz CH, Hamlin PA, Gabrilove J, Bertino JR, Portlock CS, Straus DJ, Gencarelli AN, Nimer SD, Zelenetz AD, Ann Oncol, 1/1/2007
Intra-operative acute tumor lysis syndrome during laparoscopic splenectomy preceded by splenic artery embolization
Leibowitz AB, Adamsky C, Gabrilove JL, Labow D, Surgical Laparoscopy Endoscopy & Percutaneous Techniques, 1/1/2007
Assessing symptom Burden using the MD Anderson Symptom Inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of ...
Gabrilove, JL, Perez EA, Tomita DK, Rossi G, Cleeland CS, Cancer, 1/1/2007
Ana analysis of current neutropenia therapies in cluding pegfilgrastim
Gabrilove JL, Clinical Cornerstone, 1/1/2007
Granulocyte colony stimulating factor for mucositis during post-operative radiotherapy
Gabrilove, JL, The Cancer Journal, 1/1/2006
Five-Year Follow-up of Imatinib Therapy for Newly Diagnosed Chronic Myelogenous Leukemia in Chronic-Phase Shows Sustained Responses and High Overall Survival
Brian J. Druker, M.D., François Guilhot, M.D., Stephen G. O'Brien, M.D., Ph.D., Insa Gathmann, M.Sc., Hagop Kantarjian, M.D., Norbert Gattermann, M.D., [Author 7 TBD],..., NEJM, 1/1/2006
Biology and Pathogenesis of Myelodysplastic Syndromes: Implications for the Management of Anemia
Gabrilove, JL, Oncology, 1/1/2005
Anemia and the elderly
Gabrilove, JL, Best Pract Res Clin Hematol, 1/1/2005
A Phase II Study of 24 hour Continuous Infusion of Flavopiridol in Chronic Lymphocytic Leukemia
Flinn IW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D, Larson D, Rai K, Petric R, Ramon-Suarez J, Gabrilove J, Greever M, Leukemia Res, 1/1/2005
Sequential Phase II trials of 72-hour continuous infusion and 1-hour bolus Flavopiridol for the treatment of B-cell chronic lymphocytic leukemia: results from CALGB st...
Byrd J, Pederson B L, Gabrilove J, Olatoyosi O, Grever M, Vardiman J, Larson RA, Clinical Caner Research, 1/1/2005
Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
The IRIS Study Group, The new England Journal of Medicine, 1/1/2003
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
The IRIS Study Group, The New England Journal of Medicine, 1/1/2003
Reply to statistical explanations for a community-based study of once weekly epoetin alfa therapy in patients receiving chemotherapy
Gabrilove, J, Sarokham, B, Cremieux, Journal of Clinical Oncology, 1/1/2002
Clinical benefits of epoetin alfa therapy in patients with lung cancer
Crawford,J, Demetri, G, Gabrilove, JL, Blasi, M, Sarokhan, B, Glaspy, J, Clinical Lung Cancer, 1/1/2002
Reply to More concern about transfusion requirement when evaluating quality of life in anemic patients
Gabrilove, J, Sarokham, B, Cremieux, Journal of Clinical Oncology, 1/1/2002
Clinical Benefits of epoietin-alfa therapy in patients with lung cancer
Crawford J, Demetri G, Gabrilove JL, Blasi MV, Sarokhan BJ, Glaspy J, Clin Lung Cancer, 1/1/2002
Benefits of epoietin alfa in anemic breast cancer patients receiving chemotherapy
Demetri GD, Gabrilove JL, Blasi MV, Hill RJ, Glaspy J, Clin Breast Cancer, 1/1/2002
Join now to see all

Books/Book Chapters

Filgrastim in Clinical Practice
Chapter: Filgrastim in lymphoma
Gabrilove JL, Moskowitz, Craig. HEditors: Morstyn G, Dexter M.Marcel Dekker1997
Cytokines in the treatment of hematopoietic failure
Chapter: Hematopoietic growth factors in leukemia
Gabrilove JLEditors: Ganser A, Hoelzer.Marcel Dekker1997
Neoplastic Diseases of the Blood
Chapter: Hematopoietic growth factors
Gabrilove JLEditors: Wiernik PH, Kyle RA, Dutcher JP.Churchill Livingstone, New York CityEdition 3rd,1995
The Molecular Basis of Cancer
Chapter: Growth factors in malignancy
Mendelsohn J, Gabrilove JEditors: Mendelsohn J, Howley P, Liotta L, Israel M.W. B. Saunders Company, Philadelphia1994
Scientific Basis of Transfusion Medicine
Chapter: Granulopoiesis
Gabrilove JLEditors: Anderson & Ness.W. B. Saunders Company, Philadelphia1994
Lymphoma and Leukemia
Chapter: Interleukin-1: Biological effects in human hematopoiesis
Crown J, Jakubowski A, Gabrilove J1993
Cancer: Principles and Practice of Oncology
Chapter: Hematopoietic growth factors
Gabrilove JL, Golde DWEditors: DeVita Jr. VT, Hellman S, Rosenberg SA.J. B. Lippincott, PhiladelphiaEdition 3rd,1993
The Biomodulation of Cancer
Chapter: Biological effects and clinical applications of human hematopoietic growth factors
Gabrilove J, Jakubowski AEditors: Mitchell MS.Pergamon Press, Inc., N.Y.1993
Cancer Medicine
Chapter: Hematopoietic growth factors
Gabrilove JLEditors: Holland JF, Frei E.Lea & Febiger, PhiladelphiaEdition 3rd,1993
Cytokines in Hemopoiesis, Oncology and Aids II
Chapter: Clinical trials of interleukin-1b
Jakubowski A, Gabrilove JL, Crown J, Starnes HFSpringer-Verlag, Berlin-Heidelberg-New York-Tokyo1992
Conn's Current Therapy
Chapter: Neutropenia
Gabrilove JL, Gordon MS1991
Neoplastic Diseases of the Blood
Chapter: Hematopoietic growth factors in the supportive care and treatment of patients with hematologic malignancies
Gabrilove JLEditors: Wiernik PH, Canellow GP, Kyle RA, Schiffer CA.Churchill Livingston, New York1991
Principles of Cancer Biotherapy
Chapter: Granulocyte colony-stimulating factor: Biology and clinical potential
Gabrilove JLEditors: Oldham R.Marcel Dekker, Inc., New York1991
Comprehensive Textbook of Oncology
Chapter: Hematopoietic growth factors
Gabrilove JLEditors: Moossa AR, Schimpff SC, Robson MC.Williams and Wilkins, Baltimore1991
Important advances in oncology
Chapter: Chapter 13: Colony stimulating factors: Clinical status
Gabrilove JLEditors: DeVita, Hellman, Rosenberg.J. B. Lipincott, Philadelphia1991
Cytokines in Hemopoiesis Oncology and AIDS
Chapter: Biology and clinical applications of human granulocyte colony stimulating factor
Jakubowski AA, Gabrilove JLEditors: Freund M, Link H, Welte K.Springer-Verlag, Berlin, Heidelberg1990
Cytokines in Hemopoiesis Oncology and Aids
Chapter: Phase I clinical studies of tumor necrosis factor in patients with advanced cancer
Jakubowski AA, Gabrilove JL, Chapman PB, Casper ES, Starnes HF, Oettgen HFEditors: Freund M, Link H, Welte K.Springer-Verlag, Berlin Hedielberg1990
Current opinion in oncology
Chapter: Growth factors in human cancer
Gabrilove J, Mendelsohn J1990
Current opinion in oncology
Chapter: Colony-stimulating factors
Gordon MS, Gabrilove JL1990
Hematopoietic Growth Factors
Chapter: Correction of myelosuppression with human recombinant granulocyte colony-stimulating factor
Jakubowski AA, Gabrilove JLEditors: Mertelsmann R, Herrmann F.Marcell Dekker, Inc., NY1990
Cancer chemotherapy and biological response modifiers
Chapter: Biological effects and clinical applications of human colony-stimulating factors
Gabrilove JL, Jakubowski AEditors: Pinedo HM, Longo DL, Chabner BA.Elsevier, New York1990
Oncol Viewpoints (Breast Cancer Research & Treatment)
Chapter: Colony stimulating factors
McGuire WL, Gabrilove J, Moore MAS Rinehart J1989
Modern Trends in Human Leukemia
Chapter: Biological activities of recombinant human granulocyte colony stimulating factor (rhG-CSF) and tumor necrosis factor: In vivo and in vitro analysis
Moore MAS, Welte K, Gabrilove J, Souza LMEditors: Neth, Gallo, Greaves, Janka.Springer-Verlag, BerlinEdition 7th,1987
Modern Trends in Human Leukemia VI
Chapter: Purification to apparent homogeneity and biochemical characterization of human pluripotent hematopoietic colony-stimulating factors
Gabrilove JEditors: Neth, Gallo, Greaves, Janka.Springer-Verlag, BerlinEdition 4th,1985
Join now to see all

Abstracts/Posters

Hyperlipidemia, carotenoderma, and respiratory failure: An unusual initial presentation of multiple myeloma
N. Carreau, N. Siegel, S. Saul, J. Gabrilove, K.S. Mathews, CHEST, 1/1/2015
Factors that Facilitate or Hinder Transition to Independence for Clinical and Translational Researchers: A Qualitative Research Study
Robinson GFWB, Schwartz LA, DiMeglio LA, Ahluwalia JS, Gabrilove JL, SCTS/ACRT Annual Meeting, 1/1/2014
The Mentored to Independent Transition: Survey of CTSA Education and Career Development (EDCD) Leaders
Sweeney C, Schwartz L, Toto, R, Gabrilove JL, SCTS/ACRT Meeting, 1/1/2014
Diminishing Mcl-1 protein leads to apoptosis of acute myeloid leukemia cells responding to retinoic acid differentiation
Wang R, Xia L, Gabrilove JL, Waxman S, Jing Y, AACR, 1/1/2014
Phase 1 Study of Single Agent CC-292, a highly selective bruton’s tyrosine kinase (BTK) inhibitor, in relapsed/refractory chronic lymphocytic leukemia (CLL)
Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma, S, Barnett E, Marine J, Nava-Par..., EHA, 1/1/2014
Fertility Preservation in Young Adult Cancer Patients at a Tertiary Care Center in New York
Sadie Sanchez MD, Sonia Reichert MD, Jen Kolb, Amir Steinberg MD, Randall Holcombe MD, Elizabeth Garland MD, Janice Gabrilove MD, Medical Quality 2013, the Annual Meeting of the American College of Medical Quality, 1/1/2013
Cancer Incidence in a cohort of World Trade Center Rescue and Recovery Workers, 2001-2008
Solan A, Wallenstein S, Shapiro M, Teitelbaum S, Stevenson L, Kochman A, Kaplan J, Dellenbaugh C, Kahn A, Biro FN, Crane M, Crowley L, Gabrilove J, Gonsalvez L, Harris..., CSTE, 1/1/2013
Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Jennifer R. Brown, MD, PhD, Wael A. Harb, MD, Brian T. Hill, Janice Gabrilove, MD, Jeff P. Sharman, MD, Marshall T. Schreeder, MD, MPH, Paul M. Barr, MD, James M. Fora..., ASH, 1/1/2013
Application Of The Revised IPSS (IPSS-R) and The French Prognostic Score (FPS) To Assess Overall Survival (OS) In Patients (pts) With Myelodysplastic Syndromes (MDS) T...
Thomas Prebet, MD, PhD, Zhuoxin Sun, PhD, Rhett Ketterling, MD, Peter L. Greenberg, MD, Amer M. Zeidan, MD, Mark R. Litzow, MD, Janice L. Gabrilove, MD, Harry Paul Erb..., ASH, 1/1/2013
Azacitadine with or without entinostat for the treatment of therapy related myeloid neoplasm; further results of the E1905 North American Leukemia Intergroup Study
Thomas Prebet, MD, PhD, Zhuoxin Sun, PhD, Rhett Ketterling, MD, Peter L. Greenberg, MD, Amer M. Zeidan, MD, Mark R. Litzow, MD, Janice L. Gabrilove, MD, Harry Paul Erb..., ASH, 1/1/2013
Application of the revised IPSS (IPSS-R) and the French Prognostic Score (FPS) to assess overall survival (OS) in patients (pts) with myelodysplastic syndromes (MDS) t...
Amer M. Zeidan, MD, Ju-Whei Lee, Thomas Prebet, MD PhD, Peter L. Greenberg, MD, Mark B Juckett, MD, Zhouxin Sun, PhD, Mitchell R Smith, MD, PhD, Elisabeth Paietta, PhD..., ASH, 1/1/2013
Fertility counseling in young adults with cancer
Sonia Evelyn Reichert, Sadie Sanchez, Jen Kolb, Amir S. Steinberg, Randall F. Holcombe, Elizabeth Garland, Janice Lynn Gabrilove, J Clin Oncol, 1/1/2013
Effect of phosphatidylinositol 3-kinase-delta inhibitor idelalisib (GS-1101) on signaling in primary non-Hodgkin lymphoma cells: correlative studies from NCT01306643
Adriana Arita, Katherine Hanlon, Halina Chkourko, Brian Joseph Lannutti, David Michael Johnson, Janice Lynn Gabrilove, Eileen Scigliano, Samir S. Parekh, Joshua Brody, J Clin Oncol, 1/1/2013
Application of the French prognostic score (FPS) to assess overall survival (OS) in a U.S.-based cohort of patients (pts) treated with azacytadine (Aza)
Amer Zeidan, Zhuoxin Sun, Thomas Prebet, Peter Greenberg, Mark Juckett, Mitchell Reed Smith, Elisabeth Paietta, Janice Lynn Gabrilove, Harry P. Erba, Steven Gore, Mart..., J Clin Oncol, 1/1/2013
Final Results of EFC6663: A Multicenter, International, Phase 2 Study of Alvocidib for Patients with Fludarabine-Refractory CLL
Lanasa MC, Andritsos L, Brown JR, Gabrilove JL, Caligaris-Cappio F, Ghia P, Larson RA, Kipps TJ, Leblond V, Milligan DW, Janssens A, Johnson AJ, Heerema NA, Buhler A, ..., iWCLL Meeting, 1/1/2013
Phase 1b trial of AVL-292, a covalent inhibitor of bruton’s tyrosine kinase (BTK) in chronic lymphocytic leukemia and B-non Hodgkins lymphoma
Jennifer R. Brown, Jeff Porter Sharman, Wael A. Harb, Kevin R. Kelly, Marshall T. Schreeder, John W. Sweetenham, Paul M. Barr, James M. Foran, Janice Lynn Gabrilove, T..., ASCO, 1/1/2012
Join now to see all

Lectures

Biology and clinical application of human granulocyte colony stimulating factor
Staten Island University Hospital, Staten Island, NY - 1/20/2005
The Biology and Management of MDS
Union Hospital, NJ, 2004; Great Neck, NY, 2005 - 1/15/2005
The Biology and Management of the Anemia of Cancer
Multiple Locations, 2002, 2003, 2004 - 1/10/2005
Biology of Hematopoietic Growth Factors
The Fieldston School - 1/5/2005
Biology and treatment of cancer anemia
San Diego - 1/3/2004
The Biology and management of Cancer Anemia
The University Of Pittsburgh, Pittsburgh, PA, 2002; St. Joseph’s Medical Center, Paterson, NJ, 2003 - 1/29/2003
SURPASS Trial: Results of Planned Interim Analysis
New York, NY - 1/20/2003
Neutropenia and the Role of Granulocyte Colony Stimulating Factor
The Mount Sinai School of Medicine, New York, NY - 1/15/2003
Impact of Anemia on Qol and Outcomes in Cancer Patients
New York, NY - 1/13/2003
The Role of FGF in the Clonal Evolution of CLL
1/12/2003
The biology and Management of Febrile Neutropenia
The Long Island Jewish Hospital, Manhasset, NY - 1/27/2002
Flavopiridol
Las Vegas, NV - 1/31/2000
Anti-angiogenesis in hematologic malignancies
Dallas, TX - 1/29/2000
Induction of Apoptosis: A New Treatment Strategy in Hematologic Malignancies
New York, NY - 1/21/2000
Current Treatments for leukemia
Dickenstein Cancer Treatment Center, Rye, NY - 1/20/2000
Pathophysiology of Anemia and Impact of Erythropoietin
New Orleans, LA - 1/19/2000
Pathophysiology of Anemia in Cancer Patients: Impact of Erythropoietin
New York, NY - 1/14/2000
Biology and Clinical Application of cytokines: What’s New in Oncology
1/4/2000
Optimizing Management of Chemotherapy-Induced Neutropenia: Progress in Developing Once per Cycle Cytokine Support
San Francisco CA - 1/1/2000
Hematologic Malignancies: An Opportunity for Targeted Drug Therapy
San Francisco CA - 1/1/2000
New Strategies and modalities to Optimize Patient Outcomes
San Francisco CA - 1/1/2000
Biology and Management of Cancer Anemia
Queens Hospital Center, New York, NY - 1/1/2000
Novel Treatment Strategies in CLL
1/29/1999
The biology and management of anemia of cancer
NY - 1/21/1999
Hematologic Malignancies and the research agenda
NCI, Bethesda, MD - 1/16/1999
Join now to see all

Grant Support

Strategic Curriculum For Clinical ResearchNational Center For Research Resources2005–2009
BP1 And Nuclear Hormone Signaling In Breast CancerNational Cancer Institute2006–2007
Therapeutic Strategies In Disorders Of HematopoiesisNational Cancer Institute2003–2005
Strategic Curriculum For Clinical ResearchNational Heart, Lung, And Blood Institute1999–2004
Central Nervous System-Pituitary-Adrenal InterrelationsNational Institute Of Neurological Disorders And Stroke1985–1986
NCI Physician-Investigator Development Award ProgramNational Cancer Institute1985–1986

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
Alpha Omega Alpha Honor Medical Society - AOA
Member
American Society of Hematology - ASH
Member
American Association for Cancer Research - AACR
Member
American Society of Clinical Investigation
Member
American College of Physicians - ACP
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPO
Humana ChoiceCare Network PPO
MagnaCare PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment